206 related articles for article (PubMed ID: 16670205)
41. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
[TBL] [Abstract][Full Text] [Related]
42. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
[TBL] [Abstract][Full Text] [Related]
43. Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial.
Masotti A; Zannini G; Gentile A; Morandini G
Lung Cancer; 2002 Apr; 36(1):99-103. PubMed ID: 11891040
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
[TBL] [Abstract][Full Text] [Related]
45. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
[TBL] [Abstract][Full Text] [Related]
46. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
[TBL] [Abstract][Full Text] [Related]
47. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
48. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Treat JA; Gonin R; Socinski MA; Edelman MJ; Catalano RB; Marinucci DM; Ansari R; Gillenwater HH; Rowland KM; Comis RL; Obasaju CK; Belani CP;
Ann Oncol; 2010 Mar; 21(3):540-547. PubMed ID: 19833819
[TBL] [Abstract][Full Text] [Related]
49. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
[TBL] [Abstract][Full Text] [Related]
51. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
[TBL] [Abstract][Full Text] [Related]
52. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
[TBL] [Abstract][Full Text] [Related]
53. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Socinski MA; Blackstock AW; Bogart JA; Wang X; Munley M; Rosenman J; Gu L; Masters GA; Ungaro P; Sleeper A; Green M; Miller AA; Vokes EE
J Clin Oncol; 2008 May; 26(15):2457-63. PubMed ID: 18487565
[TBL] [Abstract][Full Text] [Related]
55. Gemcitabine/carboplatin in advanced non-small cell lung cancer.
Zatloukal P; Petruzelka L
Lung Cancer; 2002 Nov; 38 Suppl 2():S33-6. PubMed ID: 12431827
[TBL] [Abstract][Full Text] [Related]
56. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
Zwitter M; Kovac V; Rajer M; Vrankar M; Smrdel U
Anticancer Drugs; 2010 Jul; 21(6):662-8. PubMed ID: 20453635
[TBL] [Abstract][Full Text] [Related]
57. [Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Wang LR; Zhang GB; Huang MZ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 36(4):391-5. PubMed ID: 17717833
[TBL] [Abstract][Full Text] [Related]
58. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Carmichael J; Allerheiligen S; Walling J
Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Kortsik C; Albrecht P; Elmer A
Lung Cancer; 2003 Apr; 40(1):85-90. PubMed ID: 12660012
[TBL] [Abstract][Full Text] [Related]
60. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Dy GK; Mandrekar SJ; Nelson GD; Meyers JP; Adjei AA; Ross HJ; Ansari RH; Lyss AP; Stella PJ; Schild SE; Molina JR; Adjei AA
J Thorac Oncol; 2013 Jan; 8(1):79-88. PubMed ID: 23232491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
